In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Dasiglucagon | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 97 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 43 (43 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 21 | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Zegalogue says: “Severe hypoglycemia in adults and children with diabetes aged 6 years and older”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Dasiglucagon | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 4848 | 1,1171067491 |
| Adverse events |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
2323 |
50449311 |
| Heart functionCardiovascular | 88 | 214198142 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1111 | 185185 |
|---|
| Appetite and food intakeMetabolic and weight | 11 | 1129517 |
|---|
| PharmacokineticsPharmacology | 33 | 969231 |
|---|
| MortalityWhole body | 11 | 504217 |
|---|
| Immune responseImmune and inflammation | 11 | 981 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Dasiglucagon differs from Human glucagon at 7 positions.
What is different
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 21 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Zealand Pharma170 participants7 Dec 2017 to 25 May 2018
Hypoglycemia · Diabetes Mellitus, Type 1
Zealand Pharma112 participants28 Jun 2017 to 13 Feb 2018
Hypoglycemia · Diabetes Mellitus, Type 1
Zealand Pharma45 participants1 Nov 2018 to 11 Mar 2019
Hypoglycemia · Diabetes Mellitus, Type 1
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Dasiglucagon | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in % | 7% Time in hypoglycemia · 80 µg dasiglucagon (D80) Dose studied: 80 µgn = 202022 | 72% Time in range Control: 47% n = 252024 |
| Gastrointestinal adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in % | 44 to 56% Nausea incidence Dose studied: 0.1, 0.3, 0.6, or 1.0 mgn not reported2018 | 45% Nausea incidence 8 weeksn = 202015 |
7%
Time in hypoglycemia · 80 µg dasiglucagon (D80)
Dose studied: 80 µgn = 202022
72%
Time in range
Control: 47%
n = 252024
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Dasiglucagon | Liraglutide |
|---|---|---|
| Heart functionCardiovascularCompared as: difference from placebo, in % | No comparable result 8 randomized-trial results measure it in another way or another unit. | 4.7% Difference in LVEF change Dose studied: 0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days7 daysn = 90 |
44 to 56%
Nausea incidence
Dose studied: 0.1, 0.3, 0.6, or 1.0 mgn not reported2018
45%
Nausea incidence
8 weeksn = 202015
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in meals/day | No comparable result 1 randomized-trial result measure it in another way or another unit. | −1 meals/day Meal replacements per day difference Dose studied: 1.2 mg per dayn = 522015 |
|---|
| PharmacokineticsPharmacologyCompared as: difference from placebo, in minutes | No comparable result 1 randomized-trial result measure it in another way or another unit. | 15 minutes tmax delay Dose studied: 1.8 mgn = 182011 |
|---|
| Adverse eventsGastrointestinalCompared as: difference from placebo, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 28% Serum lipase increase n = 9,3402017 |
|---|
| Immune responseImmune and inflammationCompared as: share of people in the arm that got the peptide, in % | No randomized trial result 1 result from other study designs. | 9.8% participants with anti-liraglutide antibodies Dose studied: 1.8 mg once daily26 weeksn not reported2009 |
|---|
No comparable result
8 randomized-trial results measure it in another way or another unit.
4.7%
Difference in LVEF change
Dose studied: 0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days7 daysn = 902016
No comparable result
1 randomized-trial result measure it in another way or another unit.
−1 meals/day
Meal replacements per day difference
Dose studied: 1.2 mg per dayn = 522015
No comparable result
1 randomized-trial result measure it in another way or another unit.
15 minutes
tmax delay
Dose studied: 1.8 mgn = 182011
No comparable result
2 randomized-trial results measure it in another way or another unit.
28%
Serum lipase increase
n = 9,3402017
No randomized trial result
1 result from other study designs.
9.8%
participants with anti-liraglutide antibodies
Dose studied: 1.8 mg once daily26 weeksn not reported2009